Filing Details

Accession Number:
0001209191-23-036078
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-06-09 19:54:20
Reporting Period:
2023-06-07
Accepted Time:
2023-06-09 19:54:20
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
921299 Fibrogen Inc FGEN Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1646395 Maykin Ho C/O Fibrogen, Inc.
409 Illinois St.
San Francisco CA 94158
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-06-07 8,289 $0.00 40,021 No 4 A Direct
Common Stock Disposition 2023-06-08 2,295 $16.79 37,726 No 4 S Direct
Common Stock Disposition 2023-06-08 6,225 $17.68 31,501 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Acquisiton 2023-06-07 12,666 $0.00 12,666 $17.13
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
12,666 2033-06-06 No 4 A Direct
Footnotes
  1. Represents the grant of restricted stock units that vest on the earlier of June 7, 2024 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date.
  2. Represents the number of shares sold by the reporting person (pursuant to a 10b5-1 trading plan dated March 3, 2023) to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I.
  3. Price reported is a weighted-average sales price. The shares were sold at prices ranging from $16.48 to $17.31. The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
  4. Price reported is a weighted-average sales price. The shares were sold at prices ranging from $17.48 to $17.865. The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
  5. Options vest on the earlier of June 7, 2024 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date.